Liraglutide - A Promising Approach Against Obesity
DOI:
https://doi.org/10.51985/JBUMDC2024455Abstract
Obesity has emerged as a global chronic condition that poses a significant public health issue. The World Health Organisation (WHO) has reported a significant increase in obesity rates, which have nearly quadrupled since 1975.1 Thus, it is crucial to consider the significant health risks associated with this issue, including the potential for developing type 2 diabetes, cardiovascular diseases, endocrinal malignancies, and musculoskeletal difficulties. Furthermore, obesity incurs substantial expenses for healthcare systems and populations at large.
References
1. Boutari, C. and C.S. Mantzoros, A 2022 update on the epidemiology of obesity and a call to action: as its twin COVID-
19 pandemic appears to be receding, the obesity and dysmetabolism pandemic continues to rage on. Metabolism, 2022.
133: p. 155217, DOI: 10.1016/j.metabol.2022.155217 .
2. Hecker, J., K. Freijer, M. Hiligsmann, and S.M.A.A. Evers,
Burden of disease study of overweight and obesity; the societal
impact in terms of cost-of-illness and health-related quality
of life. BMC Public Health, 2022. 22(1): p. 46; https://doi.org/10.1186/s12889-021-12449-2.
3. Montesi, L., M. El Ghoch, L. Brodosi, S. Calugi, G. Marchesini,
and R. Dalle Grave, Long-term weight loss maintenance for
obesity: a multidisciplinary approach. Diabetes Metab Syndr
Obes, 2016. 9: p. 37-46 doi: 10.2147/DMSO.S89836.
4. Greenway, F.L., Physiological adaptations to weight loss and
factors favouring weight regain. Int J Obes (Lond), 2015.
39(8): p. 1188-96; DOI: 10.1038/ijo.2015.59 .
5. Lin, C.-H., L. Shao, Y.-M. Zhang, Y.-J. Tu, Y. Zhang, B.
Tomlinson, P. Chan, and Z. Liu, An evaluation of liraglutide
including its efficacy and safety for the treatment of obesity.
Expert opinion on pharmacotherapy, 2020. 21(3): p. 275-285;
DOI: 10.1080/14656566.2019.1695779 .
6. Nadkarni, P., O.G. Chepurny, and G.G. Holz, Regulation of
glucose homeostasis by GLP-1. Prog Mol Biol Transl Sci,
2014. 121: p. 23-65; DOI: 10.1016/B978-0-12-800101-
1.00002-8.
7. Maselli, D., J. Atieh, M.M. Clark, D. Eckert, A. Taylor, P.
Carlson, D.D. Burton, I. Busciglio, W.S. Harmsen, A. Vella,
and A. Acosta, Effects of liraglutide on gastrointestinal
functions and weight in obesity: A randomized clinical and
pharmacogenomic trial. 2022. 30(8): p. 1608-1620; DOI:
10.1002/oby.23481 .
8. Papaetis, G.S., Liraglutide therapy in a prediabetic state:
rethinking the evidence. Current Diabetes Reviews, 2020.
16(7): p. 699-715; DOI: 10.2174/1573399816666191
230113446.
9. Wajcberg, E. and A. Amarah, Liraglutide in the management
of type 2 diabetes. Drug Des Devel Ther, 2010. 4: p. 279-90;
doi: 10.2147/DDDT.S10180 .
10. Babic, I., D. Sellers, P.L. Else, J. Nealon, A.L. Osborne, N.
Pai, and K. Weston-Green, Effect of liraglutide on neural and
peripheral markers of metabolic function during antipsychotic
treatment in rats. Journal of Psychopharmacology, 2021.
35(3): p. 284-302; DOI: 10.1177/0269881120981377.
11. Kumari, P., M. Nakata, B.Y. Zhang, Z. Otgon-Uul, and T.
Yada, GLP-1 receptor agonist liraglutide exerts central action
to induce â-cell proliferation through medulla to vagal pathway
in mice. Biochemical and Biophysical Research Communicat i o n s , 2 0 1 8 . 4 9 9 ( 3 ) : p . 6 1 8 - 6 2 5 ; D O I :
10.1016/j.bbrc.2018.03.199.
12. Trenson, L., S. Trenson, F. van Nes, C. Moyson, M. Lannoo,
E. Deleus, A. Meulemans, C. Matthys, A. Mertens, B. Van
der Schueren, and R. Vangoitsenhoven, Liraglutide for Weight
Management in the Real World: Significant Weight Loss Even
if the Maximal Daily Dose Is Not Achieved. Obes Facts,
2022. 15(1): p. 83-89; DOI: 10.1159/000520217.
13. Blackman, A., G.D. Foster, G. Zammit, R. Rosenberg, L.
Aronne, T. Wadden, B. Claudius, C.B. Jensen, and E. Mignot,
Effect of liraglutide 3.0 mg in individuals with obesity and
moderate or severe obstructive sleep apnea: the SCALE Sleep
Apnea randomized clinical trial. Int J Obes (Lond), 2016.
40(8): p. 1310-9; doi: 10.1038/ijo.2016.52.
14. Astrup, A., S. Rössner, L. Van Gaal, A. Rissanen, L. Niskanen,
M. Hakim, J. Madsen, M. Rasmussen, and M. Lean, Effects
of liraglutide in the treatment of obesity: a randomised, doubleblind, placebo-controlled study. Lancet, 2009. 374: p. 1606-
16; DOI: 10.1016/S0140-6736(09)61375-1.
15. Gorgojo-Martínez, J.J., P. Mezquita-Raya, J. Carretero-Gómez,
A. Castro, A. Cebrián-Cuenca, A. de Torres-Sánchez, M.D.
García-de-Lucas, J. Núñez, J.C. Obaya, and M.J. Soler, Clinical
recommendations to manage gastrointestinal adverse events
in patients treated with Glp-1 receptor agonists: a multidisciplinary expert consensus. Journal of Clinical Medicine, 2022.
12(1): p. 145; DOI: 10.3390/jcm12010145.
16. Seo, Y.-G., Side Effects Associated with Liraglutide Treatment
for Obesity as Well as Diabetes. Journal of Obesity & Metabolic
Syndrome, 2020. 30; doi: 10.7570/jomes20059.
17. Dimitrios, P., D. Michael, K. Vasilios, S. Konstantinos, I.
Konstantinos, P. Konstantinos, B. Spyridon, and K. Asterios,
Liraglutide as adjunct to insulin treatment in patients with
type 1 diabetes: a systematic review and meta-analysis. Current
Diabetes Reviews, 2020. 16(4): p. 313-326; DOI:
10.2174/1573399815666190614141918.
18. Javed, H., G.S. Kogilathota Jagirdhar, R. Kashyap, and P.H.
Vekaria, Liraglutide-Induced Pancreatitis: A Case Report and
Literature Review. Cureus, 2023. 15(4): p. e38263; DOI:
10.7759/cureus.38263.
19. Nafisah, S.B. and D. Almatrafi, Liraglutide overdose: A case
report and an updated review. 2020. 20(1): p. 46-49; DOI:
10.4103/2452-2473.276386.
20. Kalra, S., Follow the LEADER-Liraglutide Effect and Action
in Diabetes: Evaluation of Cardiovascular Outcome Results
Trial. Diabetes Ther, 2016. 7(4): p. 601-609; doi:
10.1007/s13300-016-0197-4.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2024 Nabila Rafi, Muhammad Sajid Abbas Jaffri, Kamran Yousuf
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
Journal of Bahria University Medical & Dental College is an open access journal and is licensed under CC BY-NC 4.0. which permits unrestricted non commercial use, distribution and reproduction in any medium, provided the original work is properly cited. To view a copy of this license, visit https://creativecommons.org/licenses/by-nc/4.0 
Deprecated: json_decode(): Passing null to parameter #1 ($json) of type string is deprecated in /home/u735751794/domains/bahria.edu.pk/public_html/ojs_jbumdc/plugins/generic/citations/CitationsPlugin.inc.php on line 49
